Table 4.
Comparison of PTC Recurrence Between the BRAF V600E + TERT C228 Mutations Group and the BRAF V600E–Only or TERT C288T–Only Group
| PTC Type and Recurrence | BRAF V600E Only (A) | TERT C228T Only (B) | BRAF + TERT Mutations (C) | Comparison of C With A |
Comparison of C With B |
||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||||
| All PTC | |||||||||
| Recurrence | |||||||||
| No. | 26 of 159 | 5 of 26 | 24 of 35 | ||||||
| % | 16.3 | 19.2 | 68.6 | ||||||
| Recurrence per 1,000 person-years | 48.96 | 32.5 | 211.76 | 3.62 | 2.07 to 6.33 | < .001 | 6.16 | 2.29 to 16.61 | < .001 |
| 95% CI | 33.34 to 71.91 | 13.53 to 78.09 | 141.94 to 315.94 | ||||||
| CPTC | |||||||||
| Recurrence | |||||||||
| No. | 22 of 136 | 4 of 19 | 20 of 28 | ||||||
| % | 16.2 | 21.0 | 71.4 | ||||||
| Recurrence per 1,000 person-years | 50.25 | 35.22 | 191.85 | 3.30 | 1.79 to 6.06 | < .001 | 5.28 | 1.76 to 15.83 | .003 |
| 95% CI | 33.08 to 76.31 | 13.22 to 93.83 | 123.77 to 297.36 | ||||||
Abbreviations: CPTC, conventional variant papillary thyroid cancer; HR, hazard ratio; PTC, papillary thyroid cancer.